Palliative treatment of malignant pleural effusion;Tratamiento paliativo del derrame pleural maligno

Medicina Paliativa

Volumn 10, Issue 3, 2003, Pages 142-148

  Porcel Pérez, José Manuel ^a  

^a HOSPITAL UNIVERSITARI ARNAU DE VILANOVA   (Spain)

Author keywords

Doxycycline; Neoplasm; Pleural effusion; Pleurodesis; Talc

Indexed keywords

BETA INTERFERON; BLEOMYCIN; CISPLATIN; DOXORUBICIN; DOXYCYCLINE; ETOPOSIDE; FLUOROURACIL; MITOMYCIN; TALC; TETRACYCLINE;

BRONCHUS OBSTRUCTION; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; HUMAN; INDWELLING CATHETER; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; PH MEASUREMENT; PLEURA EFFUSION; PLEURA FLUID; PLEURODESIS; REVIEW; SYSTEMIC DISEASE; THORACOCENTESIS; TREATMENT CONTRAINDICATION; TREATMENT INDICATION;

EID: 0141702220     PISSN: 1134248X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. Villena V, López-Encuentra A, Echave-Sustaeta J, Álvarez C, Martín-Escribano P. Estudio prospectivo de 1.000 pacientes consecutivos con derrame pleural. Etiología del derrame y características de los pacientes. Arch Bronconeumol 2002; 38: 21-6.
2. Hernández L, Romero S. Derrame pleural maligno. En: Porcel JM, editor. Enfermedades de la pleura. Lleida: Edicions de la Universitat de Lleida; 2002. p. 83-94.
3. Agudo A, González CA, Bleda MJ, Ramírez J, Hernández S, López F, et al. Occupation and risk of malignant pleural mesothelioma: a case-control study in Spain. Am J Ind Med 2000; 37: 159-68.
4. Rodríguez-Panadero F, Borderas-Naranjo F, López-Mejí as J. Pleural metastatic tumours and effusions. Frequency and pathogenic mechanisms in a post-mortem series. Eur Respir J 1989; 2: 366-9.
5. Morelock SY, Sahn SA. Drugs and the pleura. Chest 1999; 116: 212-21.
6. Heffner JE, Nietert PJ, Barbieri C. Pleural fluid pH as a predictor of survival for patients with malignant pleural effusions. Chest 2000; 117: 79-86.
7. Burrows GM, Mathews C, Colt HG. Predicting survival in patients with recurrent symptomatic malignant pleural effusions. An assessment of the prognostic values of physiologic, morphologic, and quality of life measures of extent of disease. Chest 2000; 117: 73-8.
8. Porcel JM, Vives M. Etiology and pleural fluid characteristics of large and massive effusions. Chest (en prensa).
9. Antony VB, Loddenkemper R, Astoul P, Boutin C, Goldstraw P, Hott J, et al. Management of malignant pleural effusions. Eur Respir J 2001; 18: 402-19.
10. Herrstedt J, Clementsen P, Hansen OP. Increased myelosuppression during cytostatic treatment and pleural effusion in patients with small cell lung cancer. Eur J Cancer 1992; 28A: 1070-3.
11. Li J, Gwilt P. The effect of malignant effusions on methotrexate disposition. Cancer Chemother Pharmacol 2002; 50: 373-82.
12. Rodríguez-Panadero F, Anthony VB. Therapeutic local procedures: pleurodesis. Eur Respir Mon 2002; 22: 311-26.
13. Daly MM, Kunkler IH. Chylothorax in non-Hodgkin's lymphoma managed by mediastinal radiotherapy. Clin Oncol (R Coll Radiol) 1995; 7: 397-9.
14. Díaz-Jiménez JP, Rodríguez AN. Neumología intervencionista. Barcelona: Ediciones Gea, 2000. p. 31-57.
15. Light RW. Pleural diseases. 4th ed. Philadelphia: Lippincott Williams & Wilkins, 2001. p. 108-34.
16. Porcel JM, Rodríguez-Panadero F. ¿Cuándo y cómo drenar un derrame pleural?. Med Clin (Barc) 2002; 118: 265-7.
17. Villena V, López-Encuentra A, Pozo F, De Pablo A, Martín-Escribano P. Measurement of pleural pressure during therapeutic thoracentesis. Am J Respir Crit Care Med 2000; 162: 1534-8.
18. Lan RS, Lo SK, Chuang ML, Yang CT, Tsao TC, Lee CH. Elastance of the pleural space: a predictor for the outcome of pleurodesis in patients with malignant pleural effusion. Ann Intern Med 1997; 126: 768-74.
19. Rodriguez-Panadero F, López-Mejías J. Low glucose and pH levels in malignant pleural effusions: diagnostic significance and prognostic value in respect to pleurodesis. Am Rev Respir Dis 1989; 139: 663-7.
20. Martínez-Moragón E, Aparicio J, Sanchis J, Menéndez R, Rogado MC, Sanchis F. Malignant pleural effusion: prognostic factors for survival and response to chemical pleurodesis in a series of 120 cases. Respiration 1998; 65: 108-13.
21. Aelony Y, King RR, Boutin C. Thoracoscopic talc poudrage in malignant pleural effusions. Effective pleurodesis despite low pleural pH. Chest 1998; 113: 1007-12.
22. Xie C, Teixeira LR, Mcgovern JP, Light RW. Systemic corticosteroids decrease the effectiveness of talc pleurodesis. Am J Respir Crit Care Med 1998; 157: 1441-4.
23. Rodriguez-Panadero F, Segado A, Martin-Juan J, Ayerbe R, Torres Garcia I, Castillo J. Failure of talc pleurodesis is associated with increased pleural fibrinolysis. Am J Respir Crit Care Med 1995; 151: 785-90.
24. Walker-Renard PB, Vaughan LM, Sahn SA. Chemical pleurodesis for malignant pleural effusions. Ann Intern Med 1994; 120: 56-64.
25. Vargas FS, Carmo AO, Teixeira LR. A new look at old agents for pleurodesis: notrogen mustard, sodium hydroxide, and silver nitrate. Curr Opin Pulm Med 2000; 8: 281-6.
26. Olivares-Torres CA, Laniado-Laborín R, Chávez-Garcí a C, León-Gastelum C, Reyes-Escamilla A, Light RW. Iodopovidone pleurodesis for recurrent pleural effusions. Chest 2002; 122: 581-3.
27. Putnam JB Jr. Malignant pleural effusions. Surg Clin North Am 2002; 82: 867-83.
28. Sahn SA. Is talc indicated for pleurodesis? Pro: Talc should be used for pleurodesis. J Broncol 2002; 9: 223-7.
29. Light RW. Is talc indicated for pleurodesis? Con: Talc should not be used for pleurodesis. J Broncol 2002; 9: 228-31.
30. Rehse DH, Aye RW, Florence MG. Respiratory failure following talc pleurodesis. Am J Surg 1999; 177: 437-40.
31. Weissberg D, Ben-Zeev I. Talc pleurodesis. Experience with 360 patients. J Thorac Cardiovasc Surg 1993; 106: 689-95.
32. Cardillo G, Facciolo F, Carbone L, Regal M, Corzani F, Ricci A, et al. Long-term follow-up of video-assisted talc pleurodesis in malignant recurrent pleural effusions. Eur J Cardiothorac Surg 2002; 21: 302-6.
33. de Campos JRM, Vargas FS, Werebe EC, et al Thoracoscopy talc poudrage: a 15-year experience. Chest 2001; 119: 801-6.
34. Werebe EC, Pazetti R, De Campos JRM, et al. Systemic distribution of talc after intrapleural administration in rats. Chest 1999; 115: 190-3.
35. Ferrer J, Villarino MA, Tura JM, Traveria A, Light RW. Talc preparations used for pleurodesis vary markedly from one preparation to another. Chest 2001; 119: 1901-5.
36. Fraticelli A, Robaglia-Schlupp A, Riera H, Monjanel-Mouterde S, Cau P, Astoul P. Distribution of Calibrated Talc After Intrapleural Administration: An Experimental Study in Rats. Chest 2002; 122: 1737-41.
37. Lee YCG, Teixeira LR, Devin CJ, et al. Transforming growth factor-beta(2) induces pleurodesis significantly faster than talc. Am J Respir Crit Care Med 2001; 163: 640-4.
38. Parulekar W, Di Primio G, Matzinger F, Dennie C, Bociek G. Use of small-bore vs large-bore chest tubes for treatment of malignant pleural effusions. Chest 2001; 120: 19-25.
39. Sahn SA. Malignant pleural effusions. Semin Respir Crit Care Med 2001; 22: 607-15.
40. Spiegler PA, Hurewitz AN, Groth ML. Rapid pleurodesis for malignant pleural effusions. Chest 2003; 123: 1895-8.
41. Robinson RD, Fullerton DA, Albert JD, Sorensen J, Johnston MR. Use of pleural Tenckhoff catheter to palliate malignant pleural effusion. Ann Thorac Surg 1994; 57: 286-8.
42. Pollak JS. Malignant pleural effusions: treatment with tunneled long-term drainage catheters. Curr Opin Pulm Med 2002; 8: 302-7.
43. Putnam JB Jr, Walsh GL, Swisher SG, Roth JA, Suell DM, Vaporciyan AA, et al. Outpatient management of malignant pleural effusion by a chronic indwelling pleural catheter. Ann Thorac Surg 2000; 69: 369-75.
44. Genc O, Petrou M, Ladas G, Goldstraw P. The long-term morbidity of pleuroperitoneal shunts in the management of recurrent malignant effusions. for improved management of recurrent pleural effusions. Eur J Cardiothorac Surg 2000; 18: 143-6.
45. Fry WA, Khandekar JD. Parietal pleurectomy for malignant pleural effusion. Ann Surg Oncol 1995; 2: 160-4.
46. Waller DA, Morritt GN, Forty J. Video-assisted thoracoscopic pleurectomy in the management of malignant pleural effusion. Chest 1995; 107: 1454-6.